Welcome to our dedicated page for Bioadaptives SEC filings (Ticker: BDPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioAdaptives, Inc. filings document the company’s public-reporting obligations as an OTC operating company. The Form 12b-25 notice relates to a delayed Form 10-K for the year ended December 31, 2025 and identifies the annual report process under Rule 12b-25.
For this issuer, formal disclosures center on registrant identity, reporting deadlines, annual-report timing and related compliance statements rather than product-launch detail. The filing record provides regulatory context for BioAdaptives’ nutraceutical and wellness business as it reports as a public company.
BioAdaptives (BDPT) director filed a Form 4 reporting the acquisition of 1,382 shares of Series D Convertible Preferred Stock on 11/01/2025, issued as compensation for board services. The filing lists a $0 price for the derivative award.
Each Series D share is convertible into common stock at a 100:1 ratio, corresponding to 138,200 underlying common shares, subject to a 4.9% beneficial ownership limitation. The Series D shares become convertible six months after issuance (stated as 05/01/2026), with conversion occurring immediately in a liquidation scenario. Each Series D share carries 100 votes on matters of the issuer, and the right to convert does not expire.
Mark P. Frissora, a director of BioAdaptives, Inc. (BDPT), received compensation in the form of Series D Convertible Preferred Stock on 10/01/2025. He was issued 1,517 shares of Series D Convertible Preferred Stock as board-service compensation under a Board of Directors Agreement dated 02/03/2025. Each preferred share converts into 100 shares of common stock, so the issuance represents economic exposure to 151,700 common shares, subject to a 10% beneficial ownership cap. Conversions are restricted for six months from issuance (except on liquidation), and each Series D preferred share carries 100 votes at stockholder meetings. The reporting indicates direct ownership following the transaction and no cash price was paid for the preferred shares.